A study for observing severe asthma in patients treated with tezepelumab

Study identifier:D5180R00011

ClinicalTrials.gov identifier:NCT05677139

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Asthma Control in Severe Asthma Patients Treated with Tezepelumab: A Prospective, Observational, Real-World Evidence Study (ASCENT)

Medical condition

asthma

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

550

Study type

Observational

Age

12 Years - 130 Years

Date

Study Start Date: 13 Dec 2022
Estimated Primary Completion Date: 31 Mar 2026
Estimated Study Completion Date: 31 Mar 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria